24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients (EVITA)

Sponsors and Collaborators
Novartis

Contact
Novartis Pharmaceuticals
61-324-1111 ext 0041

ClinicalTrials.gov Identifier
NCT01169701